A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7144-7152

  Fulciniti, Mariateresa ^a,b,d   Hideshima, Teru ^a   Vermot Desroches, Claudine ^e   Pozzi, Samantha ^a   Nanjappa, Puru ^a   Shen, Zhenxin ^c   Patel, Nipun ^c   Smith, Ernest S ^f   Wang, Wei ^f   Prabhala, Rao ^b   Tai, Yu Tzu ^a   Tassone, Pierfrancesco ^d   Anderson, Kenneth C ^a   Munshi, Nikhil C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c Center for Advanced Orthopedic Studies   (United States)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e IDD Biotech   (France)

^f VACCINEX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY 1339; IMMUNOGLOBULIN G1; INTERLEUKIN 6 ANTIBODY; LENALIDOMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERIFOSINE; PROTEIN KINASE B; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE REMODELING; BONE TURNOVER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; STROMA CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE AND BONES; CELL LINE, TUMOR; DEXAMETHASONE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-6; MALE; MICE; MICE, SCID; MULTIPLE MYELOMA; OSTEOCLASTS; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR;

EID: 73149112786     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1483     Document Type: Article

References (30)

1. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990;8:253-78.
2. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997;15:797-819.
3. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today 1990;11:443-9.
4. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995;182:243-8.
5. Poli V, Balena R, Fattori E, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994;13:1189-96.
6. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-72.
7. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-26.
8. Podar K, Gouill SL, Zhang J, et al. A pivotal role for Mcl-1 in bortezomib-induced apoptosis. Oncogene 2008;27:721-31.
9. Voorhees PM, Chen Q, Kuhn DJ, et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007;13:6469-78.
10. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974;291:1041-6.
11. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990;144:4226-30.
12. Reddy SV, Takahashi S, Dallas M, Williams RE, Neckers L, Roodman GD. Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J Bone Miner Res 1994;9:753-7.
13. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65.
14. Gu ZJ, De Vos J, Rebouissou C, et al. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 2000;14:188-97.
15. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995;86:685-91.
16. Emilie D, Wijdenes J, Gisselbrecht C, et al. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood 1994;84:2472-9.
17. 2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant 2005;36:771-9.
18. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114:371-9.
19. Tassone P, Neri P, Carrasco DR, et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005;106:713-6.
20. Muller R, Hildebrand T, Ruegsegger P. Noninvasive bone biopsy: a new method to analyse and display the three-dimensional structure of trabecular bone. Phys Med Biol 1994;39:145-64.
21. Ruegsegger P, Koller B, Muller R. A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int 1996;58:24-9.
22. Anderson HideshimaT. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-37.
23. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling inmultiple myeloma. Oncogene 2001;20:5991-6000.
24. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997;89:227-34.
25. Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000;275:27845-50.
26. van Zaanen HC, Lokhorst HM, Aarden LA, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 1998;102:783-90.
27. Brochier J, Legouffe E, Liautard J, et al. Immunomodulating IL-6 activity by murine monoclonal antibodies. Int J Immunopharmacol 1995;17:41-8.
28. Voorhees PM, Chen Q, Small GW, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009;145:481-90.
29. Merico F, Bergui L, Gregoretti MG, et al. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol 1993;92:27-31.
30. Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-κB signaling pathways. J Biol Chem 2008;283:11535-40.